Terms: = Prostate cancer AND AKT2, PKBBETA, 208, ENSG00000105221, RAC-BETA, P31751, PRKBB AND Treatment
129 results:
1. Breakthrough electroneutron multi-response miniature dosimetry/spectrometry in medical accelerator.
Sohrabi M; Malekitakbolagh M; Nedaei HA
Sci Rep; 2024 Apr; 14(1):9557. PubMed ID: 38664481
[TBL] [Abstract] [Full Text] [Related]
2. Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology.
Kango G; Malek R; Mannuel H; Hussain A
Curr Opin Oncol; 2024 May; 36(3):195-201. PubMed ID: 38573209
[TBL] [Abstract] [Full Text] [Related]
3. Charcot neuroarthropathy in persons with diabetes: It's time for a paradigm shift in our thinking.
Wukich DK; Frykberg RG; Kavarthapu V
Diabetes Metab Res Rev; 2024 Mar; 40(3):e3754. PubMed ID: 38069459
[TBL] [Abstract] [Full Text] [Related]
4. A novel strategy for the study on molecular mechanism of prostate injury induced by 4,4'-sulfonyldiphenol based on network toxicology analysis.
Huang S
J Appl Toxicol; 2024 Jan; 44(1):28-40. PubMed ID: 37340727
[TBL] [Abstract] [Full Text] [Related]
5. The utility of the [-2]pro-prostate-specific antigen level as a prognostic marker in patients with castration-resistant prostate cancer treated with enzalutamide.
Miyazawa Y; Hori K; Tsuji Y; Sekine Y; Arai S; Fujizuka Y; Nomura M; Koike H; Matsui H; Suzuki K
Int J Urol; 2023 Oct; 30(10):839-846. PubMed ID: 37256915
[TBL] [Abstract] [Full Text] [Related]
6. Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart review.
Yonese J; Hinata N; Masui S; Nakai Y; Shirotake S; Takeuchi A; Inamoto T; Nozawa M; Ueda K; Etsunaga T; Osawa T; Uemura M; Kimura G; Numakura K; Yamana K; Miyake H; Fukasawa S; Morishima N; Ito H; Uemura H
Int J Urol; 2023 Sep; 30(9):762-771. PubMed ID: 37248753
[TBL] [Abstract] [Full Text] [Related]
7. Caffeic acid phenethyl ester suppresses EGFR/FAK/Akt signaling, migration, and tumor growth of prostate cancer cells.
Tseng JC; Wang BJ; Wang YP; Kuo YY; Chen JK; Hour TC; Kuo LK; Hsiao PJ; Yeh CC; Kao CL; Shih LJ; Chuu CP
Phytomedicine; 2023 Jul; 116():154860. PubMed ID: 37201366
[TBL] [Abstract] [Full Text] [Related]
8. Use of expectant management based on prostate cancer risk and health status: How far are we from a risk-adapted approach?
Spratte BN; Tan HJ; Zambrano IA; Basak RS; Filson CP; Jacobs BL; Hwang S
Urol Oncol; 2023 Jul; 41(7):323.e17-323.e25. PubMed ID: 37149430
[TBL] [Abstract] [Full Text] [Related]
9. Phytochemical Analysis and Profiling of Antitumor Compounds of Leaves and Stems of
Youssef AMM; Maaty DAM; Al-Saraireh YM
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677687
[TBL] [Abstract] [Full Text] [Related]
10. Biodistribution and dosimetry for combined [
Delker A; Schleske M; Liubchenko G; Berg I; Zacherl MJ; Brendel M; Gildehaus FJ; Rumiantcev M; Resch S; Hürkamp K; Wenter V; Unterrainer LM; Bartenstein P; Ziegler SI; Beyer L; Böning G
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1280-1290. PubMed ID: 36629878
[TBL] [Abstract] [Full Text] [Related]
11. Efficacy and Safety of Radium-223 for Castration-resistant prostate cancer With Bone Metastasis Before and After Docetaxel.
Okabe KO; Terada N; Shirakawa T; Onizuka C; Kimura T; Yamashita Y; Otuka I; Ueno T; Nagano M; Takamori H; Mukai S; Kamoto T
Anticancer Res; 2022 Oct; 42(10):4981-4987. PubMed ID: 36191975
[TBL] [Abstract] [Full Text] [Related]
12. Genomic Features of Lung-Recurrent Hormone-Sensitive prostate cancer.
Fonseca NM; Van der Eecken K; Herberts C; Verbeke S; Ng SWS; Lumen N; Ritch E; Murtha AJ; Bernales CQ; Schönlau E; Moris L; Van Dorpe J; Annala M; Wyatt AW; Ost P
JCO Precis Oncol; 2022 Apr; 6():e2100543. PubMed ID: 35507889
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of open versus minimally invasive surgery in the treatment of thoracolumbar metastases.
Ntilikina Y; Collinet A; Tigan LV; Fabacher T; Steib JP; Charles YP
Orthop Traumatol Surg Res; 2022 Jun; 108(4):103274. PubMed ID: 35331924
[TBL] [Abstract] [Full Text] [Related]
14. Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference.
Fu YK; Wang BJ; Tseng JC; Huang SH; Lin CY; Kuo YY; Hour TC; Chuu CP
J Biomed Sci; 2022 Feb; 29(1):16. PubMed ID: 35197069
[TBL] [Abstract] [Full Text] [Related]
15. Exosome-mediated delivery of transforming growth factor-β receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for combination therapy of tumors.
Lee JH; Song J; Kim IG; You G; Kim H; Ahn JH; Mok H
Acta Biomater; 2022 Mar; 141():354-363. PubMed ID: 35007784
[TBL] [Abstract] [Full Text] [Related]
16. [MRI/TRUS cognitive fusion combined with 12-core systematic transperineal prostate biopsy for the diagnosis of clinically significant prostate cancer: A report of 208 cases].
Fu ZY; Sun LG; Zhang G; Gu YF; Bei ML; Hu J; Chen YC; Zhang J
Zhonghua Nan Ke Xue; 2021 May; 27(5):421-425. PubMed ID: 34914317
[TBL] [Abstract] [Full Text] [Related]
17. Immunohistochemistry for prostate Biopsy-Impact on Histological prostate cancer Diagnoses and Clinical Decision Making.
Mandel P; Wenzel M; Hoeh B; Welte MN; Preisser F; Inam T; Wittler C; Humke C; Köllermann J; Wild P; Würnschimmel C; Tilki D; Graefen M; Kluth LA; Karakiewicz PI; Chun FK; Becker A
Curr Oncol; 2021 Jun; 28(3):2123-2133. PubMed ID: 34207594
[TBL] [Abstract] [Full Text] [Related]
18. Apalutamide in Patients With Metastatic Castration-Sensitive prostate cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
Chi KN; Chowdhury S; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez A; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Brookman-May S; Mundle SD; McCarthy SA; Larsen JS; Sun W; Bevans KB; Zhang K; Bandyopadhyay N; Agarwal N
J Clin Oncol; 2021 Jul; 39(20):2294-2303. PubMed ID: 33914595
[TBL] [Abstract] [Full Text] [Related]
19. Evolving role of
Satapathy S; Sood A; Das CK; Mittal BR
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):880-890. PubMed ID: 33746213
[TBL] [Abstract] [Full Text] [Related]
20. Calculating interfractional prostate motion during radiation therapy course using fiducial markers.
Alexidis P; Tzitzikas I; Hatzimouratidis K; Chrisogonidis I
J BUON; 2021; 26(1):243-249. PubMed ID: 33721458
[TBL] [Abstract] [Full Text] [Related]
[Next]
